Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 02, 2020 | IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 | IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 03, 2020 | IVERIC bio Reports Fourth Quarter and Year End 2019 Operational Highlights and Financial Results Feb 27, 2020 | IVERIC bio to Present at the Cowen and Company 40th Annual Health Care Conference Feb 26, 2020 | IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020 Feb 20, 2020 | IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Jan 13, 2020 | IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA Dec 19, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 |
IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 |
IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 |
IVERIC bio Reports Fourth Quarter and Year End 2019 Operational Highlights and Financial Results Feb 27, 2020 |
IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020 Feb 20, 2020 |
IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Jan 13, 2020 |
IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA Dec 19, 2019 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 02, 2020 | IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 | IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 03, 2020 | IVERIC bio Reports Fourth Quarter and Year End 2019 Operational Highlights and Financial Results Feb 27, 2020 | IVERIC bio to Present at the Cowen and Company 40th Annual Health Care Conference Feb 26, 2020 | IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020 Feb 20, 2020 | IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Jan 13, 2020 | IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA Dec 19, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 |
IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 |
IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 |
IVERIC bio Reports Fourth Quarter and Year End 2019 Operational Highlights and Financial Results Feb 27, 2020 |
IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020 Feb 20, 2020 |
IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Jan 13, 2020 |
IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA Dec 19, 2019 |
